Pharmaceutical

Conduit acquires three first-in-class assets from AstraZeneca 

Conduit plans to advance two assets, AZD1656 and AZD5658, into Phase II testing for autoimmune disorders.

Aug 9, 2024 - 04:00
Conduit acquires three first-in-class assets from AstraZeneca 
Conduit plans to advance two assets, AZD1656 and AZD5658, into Phase II testing for autoimmune disorders.
Read the original article

Tags:

Previous Article

CRISPR-based Casgevy is made accessible in England following NICE guidance

Next Article

Pharmacosmos ventures into oncology and merges with G1 Therapeutics

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Malaria cases in Florida and Texas: Here’s what you need to know

Malaria cases in Florida and Texas: Here’s what you nee...

Jun 30, 2023

STAT+: Pharmalittle: We’re reading about Novo buying Catalent, Amgen’s obesity drug, and more

STAT+: Pharmalittle: We’re reading about Novo buying Ca...

Feb 5, 2024

STAT+: Eli Lilly CEO donates big to Mike Pence presidential super PAC

STAT+: Eli Lilly CEO donates big to Mike Pence presiden...

Aug 23, 2023